Start:
August 1, 2020
End:
May 2025
Enrollment:
60
Transcranial direct current stimulation (tDCS) is a safe, noninvasive, non-painful electrical stimulation of the brain that is used to support nerve cell function. Progressive damage to nerve cells in the brain leads to cognitive decline in Alzheimer's disease and related dementias. This study will test tDCS treatment to prevent or slow nerve cell damage in the brain and improve verbal memory in people with Alzheimer's disease. Participants will receive a word-list learning intervention plus either tDCS or a sham treatment for two learning cycles of two weeks each, with five sessions each week. Between the first and second cycle, there will be three months with no treatment. After each learning period, the researchers will schedule follow-up sessions with participants to conduct testing that will include functional magnetic resonance imaging (fMRI) tests, magnetic resonance spectroscopy, memory tests, and collection of physical and behavioral information.
Minimum Age: 50 Years
Maximum Age: 75 Years
Aphasic/atypical AD participants:
Amnesic/typical AD participants:
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Maryland | |
---|---|
Johns Hopkins Hospital
Baltimore,
MD
21287
Recruiting
Kyrana Tsapkini, PhD |
Lead: Johns Hopkins University
Source: ClinicalTrials.gov ID: NCT04122001
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health